




Target : KBI Biopharma Inc.

Outline : Biopharmaceutical contract analytical/process development/manufacturing services for large pharmaceutical companies and biotechnology companies

Authorized Investment : US\$50 million (maximum)



Pharmaceutical and Biotechnology companies



Further Opportunity
through the Investment

- Enhance the biopharmaceutical industry in Japan/Asia through the further expansion of currently the US/Europe-focused KBI's business into Japan/Asia, with the acquisition of cutting-edge U.S. technology and expertise in the development and manufacturing of biopharmaceuticals such as antibodies
- Drive biopharmaceutical drug discovery by establishing a value chain from research, development, and manufacturing, combined with INCJ's network of Japanese biotechnology companies and small- and medium-sized pharmaceutical companies